# Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

> **NCT03950622** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1205 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** V114
- **BIOLOGICAL:** Prevnar 13®

## Key facts

- **NCT ID:** NCT03950622
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-13
- **Primary completion:** 2020-03-30
- **Final completion:** 2020-03-30
- **Target enrollment:** 1205 (ACTUAL)
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950622, "Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03950622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*